| Name | Title | Contact Details |
|---|
As a leading franchise brokerage firm in the USA and Canada, Klimate Group is renowned for its exceptional reputation in the industry. Specializing in connecting aspiring entrepreneurs with top franchise opportunities, Klimate Group stands out for its extensive network of franchisors, personalized guidance for franchisees, and commitment to fostering successful partnerships. With a track record of matching individuals with franchises that align with their goals and values, Klimate Group has established itself as a trusted and innovative player in the franchising world, setting the standard for excellence and professionalism.
Systems Evolution, Inc. (SEI) is a business and technology consulting firm committed to delivering superior value to local clients since 1992. We pair cutting-edge technologies with custom-tailored solutions to drive powerful business results for some of the most influential companies in the world. We offer the agility, consistency, and personal attention of a local partner while providing the reach and knowledge assets of a national organization. SEI supports critical client needs in areas including Data & Analytics, Technology Enablement, Strategy & Operations, Concept to Delivery, and Security, Risk and Compliance. A 100% employee-owned business, SEI now employs hundreds of consultants across the United States. Our value proposition to both clients and employees is based on a unique business model focused on local delivery, empowerment through technology, fully customized approaches and solutions, and a culture of collaboration.
GEICO is a Maryland-based financial institution that provides personal and commercial insurance products for individuals and businesses.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.